A Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor

被引:0
|
作者
Narayanan, Anila Kutty [1 ]
Surendran, Sudhindran [1 ]
Balakrishnan, Dinesh [1 ]
Gopalakrishnan, Unnikrishnan [1 ]
Malick, Shweta [1 ]
Valsan, Arun [2 ]
Philips, Abby Cyriac [3 ]
Watson, Christopher [4 ]
机构
[1] Amrita Univ, Amrita Inst Med Sci & Res Ctr, Dept Gastrointestinal Surg & Solid Organ Transplan, Kochi 682041, Kerala, India
[2] Amrita Univ, Amrita Inst Med Sci & Res Ctr, Dept Gastroenterol & Hepatol, Kochi 682041, Kerala, India
[3] Rajagiri Hosp, Liver Inst, Dept Clin & Translat Hepatol, Aluva, Kerala, India
[4] Addenbrookes Hosp, Cambridge Univ Hosp NHS Fdn Trust, Cambridge CB2 OQQ, England
关键词
FXR; Liver metabolism; Bile acids; Obeticholic acid; FXR agonist; PRIMARY BILIARY CHOLANGITIS; NONALCOHOLIC STEATOHEPATITIS; LIVER; METABOLISM; EXPRESSION; FXR; MULTICENTER; ACTIVATION; EFFICACY; AGONIST;
D O I
10.2174/0127724328239536230919070001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Farnesoid X receptor (FXR) was identified as an orphan nuclear receptor resembling the steroid receptor in the late '90s. Activation of FXR is a crucial step in many physiological functions of the liver. A vital role of FXR is impacting the amount of bile acids in the hepatocytes, which it performs by reducing bile acid synthesis, stimulating the bile salt export pump, and inhibiting its enterohepatic circulation, thus protecting the hepatocytes against the toxic accumulation of bile acids. Furthermore, FXR mediates bile acid biotransformation in the intestine, liver regeneration, glucose hemostasis, and lipid metabolism. In this review, we first discuss the mechanisms of the disparate pleiotropic actions of FXR agonists. We then delve into the pharmacokinetics of Obeticholic acid (OCA), the first-in-class selective, potent FXR agonist. We additionally discuss the clinical journey of OCA in humans, its current evidence in various human diseases, and its plausible roles in the future.
引用
收藏
页码:225 / 233
页数:9
相关论文
共 50 条
  • [31] A PRELIMINARY STUDY OF THE EFFECTS OF OBETICHOLIC ACID, A FARNESOID X RECEPTOR AGONIST, IN PATIENTS WITH CHRONIC DIARRHOEA SECONDARY TO CROHN'S ILEAL DISEASE
    Nolan, J. D.
    Vassie, C.
    Johnston, I. M.
    Shapiro, D.
    Walters, J. R.
    GUT, 2014, 63 : A258 - A258
  • [32] THE FIRST NEW MONOTHERAPY THERAPEUTIC PBC STUDY IN A DECADE? AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID IN PBC
    Jones, D.
    Kowdley, K.
    Chapman, R.
    Burroughs, A.
    Hirschfield, G.
    Schramm, C.
    Poupon, R.
    ParEs, A.
    Shapiro, D.
    Pruzanski, M.
    GUT, 2011, 60 : A50 - A50
  • [33] THE FIRST NEW MONOTHERAPY THERAPEUTIC PBC STUDY IN A DECADE? AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID IN PBC
    Kowdley, Kris V.
    Luketic, Velimir A.
    Jones, David E.
    Chapman, Roger W.
    Burroughs, Andrew K.
    Hirschfield, Gideon M.
    Poupon, Raoul
    Schramm, Christoph
    Vincent, Catherine
    Rust, Christian
    Pares, Albert
    Mason, Andrew L.
    Castelloe, Erin N.
    Sciacca, Cathi I.
    Boehm, Olaf
    Pruzanski, Mark
    Shapiro, David A.
    HEPATOLOGY, 2011, 54 : 416A - 417A
  • [34] A leoligin derivative as farnesoid X receptor agonist and modulator of macrophage cholesterol efflux
    Ladurner, A.
    Wang, L.
    Holzer, A.
    Kovarova, L.
    Linder, T.
    Schuster, D.
    Mihovilovic, M. D.
    Atanasov, A. G.
    Dirsch, V. M.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (01) : S35 - S35
  • [35] Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3
    Fan, Yuan-Yuan
    Ding, Wen
    Zhang, Cheng
    Fu, Lin
    Xu, De-Xiang
    Chen, Xi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 77
  • [36] Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury
    Zhu, Jin-Bo
    Xu, Shen
    Li, Jun
    Song, Jin
    Luo, Biao
    Song, Ya-Ping
    Zhang, Zhi-Hui
    Chen, Yuan-Hua
    Xie, Dong-Dong
    Yu, De-Xin
    Xu, De-Xiang
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 838 : 60 - 68
  • [37] Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis
    Adorini, Luciano
    Rigbolt, Kristoffer
    Feigh, Michael
    Roth, Jonathan
    Erickson, Mary
    PLOS ONE, 2024, 19 (04):
  • [38] Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand (vol 28, pg 590, 2021)
    Yu, Junhui
    Yang, Kui
    Zheng, Jianbao
    Zhao, Wei
    Sun, Xuejun
    CANCER GENE THERAPY, 2022, 29 (06) : 871 - 872
  • [39] A LONG TERM SAFETY EXTENSION TRIAL OF THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) AND UDCA IN PRIMARY BILIARY CIRRHOSIS (PBC)
    Hirschfield, Gideon M.
    Mason, Andrew L.
    Gordon, Stuart C.
    Luketic, Velimir A.
    Mayo, Marlyn
    Vincent, Catherine
    Lindor, Keith D.
    Pares, Albert
    Kowdley, Kris V.
    Trauner, Michael
    Esguerra, Maria
    Boehm, Olaf
    Shapiro, David A.
    HEPATOLOGY, 2011, 54 : 429A - 429A
  • [40] FURTHER INCREASE IN BILIARY EXCRETION OF ASYMMETRIC DIMETHYLARGININE DURING HEPATIC ISCHEMIA/REPERFUSION INJURY BY OBETICHOLIC ACID, A FARNESOID-X-RECEPTOR AGONIST
    Di Pasqua, L. G.
    Berardo, C.
    Rizzo, V.
    Adorini, L.
    Richelmi, P.
    Vairetti, M.
    Ferrigno, A.
    DIGESTIVE AND LIVER DISEASE, 2016, 48 : E55 - E55